Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β-agonist: post-hoc analyses of KRONOS.

Journal: Respiratory research

PMID: 40340809

Abstract

BACKGROUND: In people with chronic obstructive pulmonary disease (COPD) on inhaled corticosteroid/long-acting β-agonist (ICS/LABA) therapy, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends stepping up to ICS/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) in those with exacerbations or switching to LAMA/LABA in those with major symptoms. However, the effect of stepping up to ICS/LAMA/LABA versus switching to LAMA/LABA on exacerbation risk is unclear. This analysis evaluated the effect of escalating to ICS/LAMA/LABA versus switching to LAMA/LABA or staying on ICS/LABA on lung function and exacerbation rates in symptomatic individuals with COPD without a recent exacerbation history from KRONOS.

Authors

Dave Singh

Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester, M23 9QZ, UK. dsingh@meu.org.uk.
Mona Bafadhel

King's Centre for Lung Health, School of Immunology and Microbial Sciences, Faculty of Life Science and Medicine, King's College London, London, UK.
Niki Arya

Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D, AstraZeneca, Durham, NC, USA.
Jonathan Marshall

Global Medical Affairs - Respiratory, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Himanshu Parikh

Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Dobrawa Kisielewicz

Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Charlotta Movitz

Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Karin Bowen

Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Mehul Patel

Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Keywords

Administration, Inhalation Adrenal Cortex Hormones Adrenergic beta-2 Receptor Agonists Aged Bronchodilator Agents Double-Blind Method Drug Combinations Drug Substitution Drug Therapy, Combination Female Humans Male Middle Aged Muscarinic Antagonists Pulmonary Disease, Chronic Obstructive Treatment Outcome

External Resources

View on PubMed Access via DOI PubMed (40340809)

Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β-agonist: post-hoc analyses of KRONOS.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals